Figure 3

Dose-response and time-course of myelin gene expression in CG4-EPOR cells upon EPO treatment. (A-B) CG4-EPOR cells were differentiated and treated with different concentrations of EPO. MOG (A) and MBP (B) gene expression were analyzed by qPCR at d 6 of differentiation. Results are expressed as arbitrary units versus untreated (no EPO) cells and are the mean ± SD of six to nine samples from three independent experiments analyzed in duplicate (panel A, MOG: no EPO, N = 9; EPO doses of 0.004 and 0.4 ng/mL, N = 6; EPO doses of 8, 80 and 400 ng/mL, N = 9; panel B, MBP: no EPO, N = 6; EPO doses of 0.004 and 0.4 ng/mL, N = 6; EPO doses of 8, 80 and 400 ng/mL, N = 6). *P < 0.05; ***P < 0.001 versus no EPO by Dunnett’s method. (C-D) CG4-EPOR cells were differentiated and treated with or without EPO 80 ng/mL. MOG (C) and MBP(D) gene expression were analyzed by qPCR at 2, 4 and 6 d of differentiation. The results are expressed as arbitrary units versus undifferentiated (time 0) cells and are the mean ± SD of four to six samples from two independent experiments analyzed in duplicate. *P< 0.05; **P< 0.01; ***p< 0.001 versus no EPO at the same time point by Student t test.